Endothelial Colony Forming Cells (ECFCs) in murine AKI - implications for future cell-based therapies

Area of Science:

• Nephrology
• Regenerative Medicine
• Vascular Biology

Background:

• Early Endothelial Progenitor Cells (eEPCs) show efficacy in murine ischemic AKI.
• Limited data exists on late EPCs (ECFCs) in ischemic AKI.
• Investigating ECFCs' role in post-ischemic kidney function and related mechanisms is crucial.

Purpose of the Study:

• To evaluate the effects of Endothelial Colony Forming Cells (ECFCs) on post-ischemic kidney function over several weeks.
• To analyze ECFCs' impact on endothelial-to-mesenchymal transition (EndoMT), peritubular capillary density (PTCD), and endothelial markers (aT, p62).

Main Methods:

• Mice underwent bilateral renal pedicle clamping (35 or 45 min).
• Syngeneic ECFCs were intravenously injected post-ischemia.
• Kidney function, fibrosis, PTCD, EndoMT, aT, and p62 were assessed at 1, 4, and 6 weeks.

Main Results:

• ECFCs improved kidney function only at week 1.
• Ischemia-induced fibrosis was reduced by ECFCs, but PTCD loss was unaffected.
• ECFCs partially reduced EndoMT in one group and aggravated endothelial aT decline; p62 levels were not modulated.

Conclusions:

• Single-dose ECFCs reduce long-term fibrosis but offer only transient functional improvement.
• ECFCs differ from eEPCs, not preventing capillary loss or altering p62.
• ECFC therapy is less effective than eEPC therapy in mitigating ischemia-induced kidney damage.